AUTH/1848/6/06: Janssen-Cilag held responsible for PR agency offering £200 to journalists to attend NICE hearing

📅 2006 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/1848/6/06
PartiesMedia/Director v Janssen-Cilag
ProductEprex (epoetin alfa)
IssuePR agency offered journalists £200 to attend a NICE appeal hearing
Complaint sourcePR Week article (“in NICE apology for media cash carrot”)
Applicable Code year2003
Breach clauses2, 9.1 and 19.1
Key reasoningCompany responsible for actions/omissions of agents acting on its behalf; insufficient local clarity and oversight; verbal assumptions/training not enough; pre-use submission of materials might have prevented the issue
SanctionsUndertaking received; Additional sanctions: Advertisement
DatesComplaint received 19 June 2006; Proceedings commenced 20 June 2006; Case completed 25 September 2006 (site lists completed 24 September 2006)

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A PR Week article reported that, ahead of a NICE appeal hearing, a PR company emailed reporters offering £200 if they attended the hearing.
  • The hearing related to NICE’s rejection of erythropoietins for chemotherapy-induced anaemia; Eprex (epoetin alfa) was referenced as a Janssen-Cilag product.
  • Janssen-Cilag said it was unaware of the offer and that it was an unauthorised act by an individual at the PR company, contrary to policy and contractual terms.
  • NICE’s chairman publicly condemned the financial incentive; the PR company retracted and apologised, stating the client did not know and would not have sanctioned it.
  • The PMCPA considered the PR company was acting as Janssen-Cilag’s agent; therefore Janssen-Cilag was responsible under the Code.
  • Janssen-Cilag appealed the findings under Clauses 2 and 9.1 (it accepted the Clause 19.1 breach).
⚖️

Outcome

  • Breach found (Applicable Code year: 2003).
  • Panel ruled breaches of Clauses 2, 9.1 and 19.1.
  • On appeal, the Appeal Board upheld the Panel’s rulings for Clauses 2 and 9.1 and noted Janssen-Cilag had accepted the Clause 19.1 breach.
  • Appeal Board found there was insufficient local clarity on the PR agency’s responsibilities under the UK Code and that Janssen-Cilag had not actively managed the agency or taken all reasonable steps to prevent a breach.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training